Lisa K. Stockdale

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications

B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.

B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.

Journal: Frontiers in immunology
Published: November 10, 2025

Quantitative measures of human Cytomegalovirus infection and their associations with tuberculosis disease progression and Mycobacterium tuberculosis infection.

Quantitative measures of human Cytomegalovirus infection and their associations with tuberculosis disease progression and Mycobacterium tuberculosis infection.

Journal: Philosophical transactions of the Royal Society of London. Series B, Biological sciences
Published: November 06, 2025

R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial.

R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial.

Journal: Frontiers in immunology
Published: April 29, 2025

Vaccine-induced responses to R21/Matrix-M - an analysis of samples from a phase 1b age de-escalation, dose-escalation trial.

Vaccine-induced responses to R21/Matrix-M - an analysis of samples from a phase 1b age de-escalation, dose-escalation trial.

Journal: Frontiers in immunology
Published: April 29, 2025

Salmonella Typhi gut invasion drives hypoxic immune subsets associated with disease outcomes.

Salmonella Typhi gut invasion drives hypoxic immune subsets associated with disease outcomes.

Journal: Nature communications
Published: March 02, 2025

The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E.

The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E.

Journal: NPJ vaccines
Published: September 25, 2024

Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines.

Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines.

Journal: NPJ vaccines
Published: April 30, 2024

A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.

A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.

Journal: NPJ vaccines
Published: February 20, 2024

A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's disease.

A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's disease.

Journal: EBioMedicine
Published: December 18, 2023

The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.

The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.

Journal: The Lancet. Infectious diseases
Published: October 09, 2023

R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.

R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.

Journal: The Lancet. Microbe
Published: October 05, 2023

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Journal: The Lancet. Microbe
Published: October 05, 2023
Showing 1-12 of 51

Last Updated: 09/26/2026